Eli Lilly’s stock prices ticked up following the company’s announcement of strong quarterly sales and positive Phase III results in severe atopic dermatitis.
CVS Health Corp.’s pharmacy benefit management (PBM) unit is launching a new program under which employers and insurers will be able to offer diabetes drugs, including insulin, at no out-of-pocket costs to their members.
The U.S. Food and Drug Administration approved Boehringer Ingelheim Pharmaceuticals and Eli Lilly’s Trijardy XR for lowering blood sugar in adults with type 2 diabetes.
Indianapolis-based Eli Lilly is adding 462 new jobs in Durham County, North Carolina over five years.
Novo Nordisk is involved in a clinical trial using the company’s GLP-1 analog diabetes drug Victoza to evaluate if the medicine can improve brain function and cognition in Alzheimer’s patients.
Novo Nordisk’s Ozempic (semaglutide) won approval from the U.S. Food and Drug Administration to reduce the risk of major adverse cardiovascular events such as heart attack, stroke, or death in adults with type 2 diabetes and known heart disease.
Eli Lilly and Co. plans to sell two versions of insulin products at half their current U.S. list prices, eight months after the drug manufacturer started selling a half-priced version of the widely used Humalog injection.
The U.S. Food and Drug Administration approved Novo Nordisk’s Fiasp (insulin aspart injection) 100 u/mL for use as a new mealtime insulin option for children with diabetes.
Companies from across the globe provide updates on their business and pipeline progress.
Diabetes medications and blood-test supplies are sold, traded and donated on black markets because the U.S. healthcare system is not meeting patients’ needs, a study shows.
